Jeil Pharmaceutical Co.,Ltd (KRX:271980)
13,730
-220 (-1.58%)
Apr 2, 2026, 3:30 PM KST
KRX:271980 Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 48,874 | 53,476 | 32,991 | 31,446 | 25,963 |
Short-Term Investments | 4,269 | 3,980 | 2,667 | 142.46 | 2,040 |
Trading Asset Securities | 5,689 | - | - | - | - |
Cash & Short-Term Investments | 58,832 | 57,455 | 35,658 | 31,589 | 28,003 |
Cash Growth | 2.40% | 61.13% | 12.88% | 12.80% | 325.06% |
Accounts Receivable | 136,848 | 160,467 | 150,955 | 137,807 | 129,424 |
Other Receivables | 4,136 | 13,440 | 15,171 | 15,454 | 15,265 |
Receivables | 140,984 | 173,908 | 166,126 | 153,262 | 146,689 |
Inventory | 104,475 | 104,427 | 109,768 | 99,151 | 102,458 |
Prepaid Expenses | 515.62 | 214.62 | 327.84 | 291.88 | 186.71 |
Other Current Assets | 6,816 | 7,031 | 5,167 | 7,348 | 7,336 |
Total Current Assets | 311,621 | 343,036 | 317,046 | 291,641 | 284,672 |
Property, Plant & Equipment | 147,726 | 146,166 | 137,041 | 138,402 | 125,710 |
Long-Term Investments | 25,016 | 8,342 | 7,343 | 6,798 | 5,032 |
Other Intangible Assets | 8,854 | 4,994 | 4,320 | 3,888 | 3,762 |
Long-Term Accounts Receivable | -0 | 0 | -0 | 0 | 0 |
Long-Term Deferred Tax Assets | 9,259 | 7,428 | 5,359 | 172.39 | 1,452 |
Long-Term Deferred Charges | 6,583 | 8,378 | 8,561 | 5,494 | - |
Other Long-Term Assets | 1,515 | 7,356 | 7,656 | 10,496 | 5,858 |
Total Assets | 510,575 | 525,700 | 487,326 | 456,892 | 426,486 |
Accounts Payable | 89,019 | 134,562 | 144,338 | 151,641 | 153,084 |
Accrued Expenses | 170.84 | 178.21 | 160.74 | 99.91 | 29.33 |
Short-Term Debt | 90,487 | 71,000 | 64,772 | 40,576 | 24,166 |
Current Portion of Long-Term Debt | - | - | - | 2,500 | 6,125 |
Current Portion of Leases | 1,845 | 1,971 | 1,946 | 1,832 | 1,915 |
Current Income Taxes Payable | 1,794 | 3,588 | 448.24 | 1,049 | 114.57 |
Other Current Liabilities | 59,137 | 80,391 | 92,710 | 62,667 | 36,509 |
Total Current Liabilities | 242,454 | 291,690 | 304,375 | 260,366 | 221,943 |
Long-Term Debt | - | - | - | 3,999 | 8,977 |
Long-Term Leases | 1,084 | 2,725 | 4,452 | 5,443 | 6,617 |
Pension & Post-Retirement Benefits | 15,918 | 11,771 | 6,733 | 25.04 | 1,262 |
Other Long-Term Liabilities | 94.11 | 197.01 | 938.52 | 23,170 | 20,339 |
Total Liabilities | 259,549 | 306,383 | 316,499 | 293,003 | 259,139 |
Common Stock | 7,352 | 7,352 | 7,352 | 7,352 | 7,352 |
Additional Paid-In Capital | 206,399 | 206,223 | 155,296 | 155,296 | 155,296 |
Retained Earnings | -29,336 | -52,296 | -19,660 | -20,321 | -10,414 |
Treasury Stock | -4,829 | -4,829 | -4,829 | -4,829 | -4,432 |
Comprehensive Income & Other | 31,484 | 31,699 | 20,410 | 20,410 | 20,410 |
Total Common Equity | 211,071 | 188,150 | 158,570 | 157,909 | 168,213 |
Minority Interest | 39,954 | 31,167 | -1,538 | -2,312 | -866.16 |
Shareholders' Equity | 251,025 | 219,317 | 170,828 | 163,889 | 167,347 |
Total Liabilities & Equity | 510,575 | 525,700 | 487,326 | 456,892 | 426,486 |
Total Debt | 93,416 | 75,695 | 71,170 | 54,350 | 47,800 |
Net Cash (Debt) | -34,585 | -18,240 | -35,513 | -22,761 | -19,797 |
Net Cash Per Share | -2373.77 | -1252.00 | -2437.13 | -1561.68 | -1355.11 |
Filing Date Shares Outstanding | 14.56 | 14.57 | 14.57 | 14.57 | 14.58 |
Total Common Shares Outstanding | 14.56 | 14.57 | 14.57 | 14.57 | 14.58 |
Working Capital | 69,168 | 51,345 | 12,671 | 31,275 | 62,729 |
Book Value Per Share | 14493.41 | 12912.16 | 10882.20 | 10836.83 | 11533.52 |
Tangible Book Value | 202,217 | 183,156 | 154,250 | 154,021 | 164,451 |
Tangible Book Value Per Share | 13885.44 | 12569.44 | 10585.71 | 10570.02 | 11275.56 |
Land | 54,461 | 53,698 | 40,613 | 40,586 | 30,106 |
Buildings | 107,964 | 105,484 | 103,864 | 103,864 | 102,213 |
Machinery | 93,164 | 88,787 | 88,622 | 82,315 | 76,560 |
Construction In Progress | 6,082 | 4,724 | 3,070 | 3,717 | 2,390 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.